Medicaid managed-care plans are looking to state officials for help as they face massive outlays for the new hepatitis C drug Sovaldi, which costs $84,000 for a 12-week course of treatment.
Medicaid managed-care plans are looking to state officials for help as they face massive outlays for the new hepatitis C drug Sovaldi, which costs $84,000 for a 12-week course of treatment.
The companies that administer the Medicaid plans are eager to raise the matter with state officials and Congress because conversations are beginning now to set the 2015 rates, Jeff Myers, president and CEO of the trade group Medicaid Health Plans of America, said in an April 28 letter to the National Association of Medicaid Directors (PDF). The trade group is asking the Medicaid directors to form a workgroup to tackle the problem.
Plans in some states are considering eliminating coverage for the drug, having Medicaid agencies pay for it above the capitation rate paid to plans, or building the drug into the rates paid by state agencies, Myers said. Medicaid agencies in Louisiana, California, Michigan and Florida have already limited access to the drug based on case-by-case determinations.
Read the full story here: http://bit.ly/1hdLevE
Source: Modern Healthcare
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More